[Featured Stock] SK Chemicals Rises 7% on AstraZeneca's Anticipated US FDA Approval

[Asia Economy Reporter Minji Lee] SK Chemicals is showing a surge of over 7% during trading hours. This appears to reflect expectations that the AstraZeneca vaccine, which it manufactures under contract, will receive emergency use authorization from the U.S. Food and Drug Administration (FDA).

At 10:52 a.m. on the 18th, SK Chemicals was trading at 374,000 KRW, up 7.01% from the previous trading day. During the day, SK Chemicals traded as high as 378,000 KRW.

On the 17th (local time), Dr. Fauci, director of the National Institute of Allergy and Infectious Diseases, said regarding the approval of AstraZeneca’s vaccine, “Data will be sent to the FDA within one week or at most two weeks.” He added, “A committee must be convened to review whether the package for emergency use authorization is appropriate and to monitor safety, but (this process) will definitely take weeks, not months.”